Difference between revisions of "Dasatinib (Sprycel)"
Jump to navigation
Jump to search
m |
|||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Acute lymphocytic leukemia]] | ||
| + | *[[Chronic myelogenous leukemia]] | ||
| + | *[[Mast cell diseases]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 12: | Line 17: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *6/28/06: FDA approved for the treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. | + | *6/28/06: FDA approved for the treatment of adults with [[Chronic myelogenous leukemia | chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia]] with resistance or intolerance to prior therapy including [[Imatinib (Gleevec) | imatinib]]. Also indicated for the treatment of adults with [[Acute lymphocytic leukemia | Philadelphia chromosome-positive acute lymphoblastic leukemia]] with resistance or intolerance to prior therapy. |
| − | + | *10/28/2010: New indication for "newly diagnosed adults with [[Chronic myelogenous leukemia | Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase]]. | |
| + | |||
==Also known as== | ==Also known as== | ||
BMS-354825 | BMS-354825 | ||
| Line 29: | Line 35: | ||
[[Category:SRC inhibitors]] | [[Category:SRC inhibitors]] | ||
[[Category:SYK inhibitors]] | [[Category:SYK inhibitors]] | ||
| + | |||
[[Category:Acute lymphocytic leukemia medications]] | [[Category:Acute lymphocytic leukemia medications]] | ||
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
| + | [[Category:Mast cell diseases]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2006]] | ||
Revision as of 02:25, 28 October 2014
General information
Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Dasatinib (Sprycel) package insert pages 8-9[1]
- Dasatinib (Sprycel) patient drug information (Chemocare)[4]
- Dasatinib (Sprycel) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/28/06: FDA approved for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
- 10/28/2010: New indication for "newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
Also known as
BMS-354825